Trends in the Susceptibility of Clinically Important Resistant Bacteria to Tigecycline: Results from the Tigecycline In-vitro Surveillance in Taiwan (TIST), 2006-2010.

Link to article at PubMed

Trends in the Susceptibility of Clinically Important Resistant Bacteria to Tigecycline: Results from the Tigecycline In-vitro Surveillance in Taiwan (TIST), 2006-2010.

Antimicrob Agents Chemother. 2011 Dec 27;

Authors: Chen YH, Lu PL, Huang CH, Liao CH, Lu CT, Chuang YC, Tsao SM, Chen YS, Liu YC, Chen WY, Jang TN, Lin HC, Chen CM, Shi ZY, Pan SC, Yang CL, Kung HC, Liu CE, Cheng YJ, Liu JW, Sun W, Wang LS, Ko WC, Yu KW, Chiang PC, Lee MH, Lee CM, Hsu GJ, Hsueh PR

Abstract
The Tigecycline In-vitro Surveillance in Taiwan (TIST), a nationwide, prospective surveillance during 2006 to 2010, collected a total of 7,793 clinical isolates, including methicillin-resistant Staphylococcus aureus (MRSA) (n=1,834), penicillin-resistant Streptococcus pneumoniae (PRSP) (n=423), vancomycin-resistant enterococci (VRE) (n=219), extended-spectrum ?-lactamase (ESBL)-producing Escherichia coli (n=1,141), ESBL-producing Klebsiella pneumoniae (n=1,330), Acinetobacter baumannii (n=1,645), and Stenotrophomonas maltophilia (n=903), from different specimens from 20 different hospitals in Taiwan. Minimum inhibitory concentrations (MICs) of tigecycline were determined following the criteria of the US Food and Drug Administration (FDA) and European Committee on Antimicrobial Susceptibility Testing (EUCAST-2011).Among drug-resistant Gram-positive pathogens, all of the PRSP isolates were susceptible to tigecycline (MIC(90), 0.03 ?g/ml) and only one MRSA isolate (MIC(90), 0.5 ?g/ml) and three VRE isolates (MIC(90), 0.125 ?g/ml) were non-susceptible to tigecycline. Among the Gram-negative bacteria, the tigecycline susceptibility rates were 99.65% for ESBL-producing E. coli (MIC(90), 0.5 ?g/ml) and 96.32% for ESBL-producing K. pneumoniae (MIC(90), 2 ?g/ml), when interpreted by FDA criteria, but were 98.7% and 85.8%, respectively, when interpreted by EUCAST-2011 criteria. The susceptibility of A. baumannii (MIC(90), 4 ?g/ml) decreased from 80.9% in 2006 to 55.3% in 2009, but increased to 73.4% in 2010. A bimodal MIC distribution was found among carbapenem-susceptible A. baumannii isolates and an unimodal MIC distribution was found among carbapenem-nonsusceptible A. baumannii isolates. In Taiwan, tigecycline continues to have excellent in vitro activity against several major clinically important drug-resistant bacteria, with the exception of A. baumannii.

PMID: 22203598 [PubMed - as supplied by publisher]

Leave a Reply

Your email address will not be published.